BEIJING--March 23, 2022--Researched by Industrial Info Resources (Sugar Land, Texas)--So far, three kinds of gene/cell therapy drugs in China have attained a China Food and Drug Administration (CFDA) license: a recombinant human p53 adenovirus injection; a recombinant human adenovirus type-5 injection; and a CAR-T cell therapy product (developed by FosunKite Bio).